<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04391907</url>
  </required_header>
  <id_info>
    <org_study_id>2019-07-016</org_study_id>
    <nct_id>NCT04391907</nct_id>
  </id_info>
  <brief_title>Clinical Efficacy of Intense Pulsed Light(IPL) Procedure in Dry Eye Patient</brief_title>
  <official_title>Clinical Efficacy of Intense Pulsed Light(IPL) Procedure in Dry Eye Patients With Meibomian Gland Dysfunction Prior to Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical efficacy of Intense Pulsed Light(IPL) procedure in dry eye patients with meibomian
      gland dysfunction prior to cataract surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      IPL procedure are known to effective for the treatment of meibomian gland dysfunction. In
      this study, we are investigating the use of IPL before cataract surgery for the improvement
      of dry eye symptom after cataract surgery.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 20, 2020</start_date>
  <completion_date type="Anticipated">March 2, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TBUT</measure>
    <time_frame>3 months</time_frame>
    <description>tear break-up time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>meibomian gland function score</measure>
    <time_frame>3 months</time_frame>
    <description>By expression of eyelid, scoring of expressibility and quality of meibon will be tested.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OSDI</measure>
    <time_frame>3 months</time_frame>
    <description>questionnaire to evaluate dry eye symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Corneal staining score</measure>
    <time_frame>3 months</time_frame>
    <description>Punctate epithelial erosion of cornea will be evaluated with standard classification system.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Dry Eye Syndromes</condition>
  <arm_group>
    <arm_group_label>IPL group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject who have intense pulsed light (IPL) laser 2 twice 1-6 weeks before cataract surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-IPL group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subject who do not have intense pulsed light (IPL) laser before cataract surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>IPL</intervention_name>
    <description>Intense pulse light (IPL) laser is used for the treatment of dry eye originated from meibomian gland dysfunction. IPL laser will be performed to patients who are planned to cataract surgery to improve dry eye.</description>
    <arm_group_label>IPL group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A patient at the age of 21 cataract surgery

          2. A patient has the visual potential of 20/25 or better in each eye after cataract
             removal

          3. Dry eye patient by meibomian gland dysfunction

          4. Written informed consent to surgery and participation in the study

        Exclusion Criteria:

          1. Eye damage, active eye infection

          2. Uncontrolled health problem

          3. Wear contact lens within one month

          4. Allergic reactions of fluorescein sodium or ophtalmic anesthetic

          5. Eye surgery and trauma in the last six months

          6. Eye disease, structural abnormality

          7. If there is a cause of vision loss other than cataracts

          8. Under 20/25 expect vision

          9. Under the age of 20 years of age

         10. Pregnant woman and lactating woman

         11. Medical conditions in which IPL is contraindicated
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tae-Young Chung, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tae-Young Chung, PhD</last_name>
    <phone>+82-2-3410-3548</phone>
    <email>taeyoung15.chung@samsaung.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dong Hui Lim, PhD</last_name>
    <phone>+82-2-3410-3548</phone>
    <email>ldhlse@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 15, 2020</study_first_submitted>
  <study_first_submitted_qc>May 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2020</study_first_posted>
  <last_update_submitted>May 15, 2020</last_update_submitted>
  <last_update_submitted_qc>May 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>tae-young chung</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

